An injectable biomaterial vaccine encapsulating antigens associated with acute myeloid leukaemia, dendritic-cell-targeting pro-inflammatory cytokines and an adjuvant protects mice from the disease.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$99.00 per year
only $8.25 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Döhner, H. et al. N. Engl. J. Med. 373, 1136–1152 (2015).
Estey, E. et al. Lancet 368, 1894–1907 (2006).
Podoltsev, N. et al. Blood Rev. 31, 43–62 (2017).
Grosso, D. et al. Cancer 121, 2689–2704 (2015).
Anguille, S. et al. Leukemia 26, 2186–2196 (2012).
Shi, Y. et al. Blood Adv. 2, 3177–3192 (2018).
Shah, N. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-019-0503-3 (2020).
Ali, O. et al. Sci. Transl. Med. 1, 8ra19 (2009).
Galluzzi, L. et al. Cancer Cell 28, 690–714 (2015).
About this article
Cite this article
Chen, G., Gu, Z. A prophylactic and a therapeutic against AML. Nat Biomed Eng 4, 4–5 (2020). https://doi.org/10.1038/s41551-019-0509-x